TY - GEN
T1 - Colony-stimulating factor - in vitro and in vivo effect
AU - Niho, Y.
AU - Okamura, S.
AU - Harada, M.
AU - Shibuya, T.
AU - Kimura, N.
AU - Tanaka, T.
AU - Akashi, K.
PY - 1989
Y1 - 1989
N2 - Colony stimulating factor (CSF) was initially named for the activity or factor which modulated colony formations of mature granulocytes originated from a progenitor cell in bone marrow in a culture dish. In this article, we described a detective system for CSF, CSF-producing tumor which strongly suggested to us that CSF was not only a factor in vitro phenomenon but also a factor working actually in vivo. Finally, we presented a few experiences of administration of recombinant CSF to experimental animals and finally several cases of clinical trials of CSF which seem to be very potent and able agents for granulopenic patients.
AB - Colony stimulating factor (CSF) was initially named for the activity or factor which modulated colony formations of mature granulocytes originated from a progenitor cell in bone marrow in a culture dish. In this article, we described a detective system for CSF, CSF-producing tumor which strongly suggested to us that CSF was not only a factor in vitro phenomenon but also a factor working actually in vivo. Finally, we presented a few experiences of administration of recombinant CSF to experimental animals and finally several cases of clinical trials of CSF which seem to be very potent and able agents for granulopenic patients.
UR - http://www.scopus.com/inward/record.url?scp=0024853278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024853278&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:0024853278
SN - 0444813489
T3 - New horizons of tumor immunotherapy: proceedings of the International Symposium on new horizons of tumor immunotherapy. ICS852
SP - 501
EP - 521
BT - New horizons of tumor immunotherapy
A2 - Torisu, M.
A2 - Yoshida, T.
A2 - Torisu, M.
A2 - Yoshida, T.
PB - Elsevier Science Publishers B.V.
T2 - The International Symposium on new horizons of tumor immunotherapy
Y2 - 30 November 1988 through 2 December 1988
ER -